Postoperative vedolizumab in Crohn's disease: interpreting persistence, endoscopic recurrence, and treatment strategy
Digestive and Liver Disease · 2026-11
DOI: 10.1016/j.dld.2026.10.030 ↗Kurz gefasst
Leserbrief in der Zeitschrift Digestive and Liver Disease, 2026-11. Verfasst von Leyi Xu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, the Affiliated Hospital of Southwest Medical University, Sichuan, China. Electronic address: xuleyi582@gmail.com. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Laboratory Medicine, the Affiliated Hospital of Southwest Medical University, Sichuan, China. Electronic address: xuleyi582@gmail.com.
- Department of Laboratory Medicine, the Affiliated Hospital of Southwest Medical University, Sichuan, China. Electronic address: yeting1103@163.com.
Zitieren
APA
Xu, L., & Ye, T. (2026). Postoperative vedolizumab in Crohn's disease: interpreting persistence, endoscopic recurrence, and treatment strategy. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2026.10.030
Vancouver
Xu L, Ye T. Postoperative vedolizumab in Crohn's disease: interpreting persistence, endoscopic recurrence, and treatment strategy. Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2026.10.030
BibTeX
@article{Xu2026,
author = {Xu, Leyi and Ye, Ting},
title = {Postoperative vedolizumab in Crohn's disease: interpreting persistence, endoscopic recurrence, and treatment strategy},
journal = {Digestive and Liver Disease},
year = {2026},
doi = {10.1016/j.dld.2026.10.030}
}
EUVIMED